Review article: Bone and joint diseases in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 5, 1998, Pages 397-404

  De Vos, M ^a   De Keyser, F ^a   Mielants, H ^a   Cuvelier, C ^a   Veys, E ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; DEOXYPYRIDINOLINE; ETIDRONIC ACID; GLUCOCORTICOID; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; PYRIDINOLINE; SALAZOSULFAPYRIDINE; VITAMIN D;

ARTHRITIS; ARTHROPATHY; BONE DISEASE; BONE MASS; DISEASE ASSOCIATION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; HIP FRACTURE; HORMONAL THERAPY; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SACROILIITIS; SPONDYLITIS; VERTEBRA FRACTURE;

ANIMALS; BONE DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; JOINT DISEASES;

EID: 0031835457     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00325.x     Document Type: Review

References (65)

1. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988; 83: 703-9.
2. Greenstein AJ, Jarowitz HD, Scalar BD. The extra-intestinal manifestations of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55: 401-12.
3. Haslock I, Wright V. The musculoskeletal complications of Crohn's disease. Medicine 1975; 52: 217-25.
4. Protzer U, Duchmann R, Höhler T, et al. Enteropathic spondyloarthropathy in chronic inflammatory bowel disease: prevalence, pattern of manifestations and HLA-association. Ed Klin 1996; 91: 330-5.
5. Dougados M, van der Linden J, Juhlin R, et al. The European Spondyloarthropathy Group: The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy. Arthritis Rheum 1991; 34: 1218-26.
6. Mielants H, Veys EM, Goethals K, et al. Destructive lesions of small joints in seronegative spondyloarthropathies: relation to gut inflammation. Clin Exp Rheumatol 1990; 8: 23-7.
7. Huaux JP, Faissi R, De Bruyere M. HLA B27 in regional enteritis with and without ankylosing spondylitis or sacroilitis. J Rheumatol 1997; 4(Suppl. 3): 60-3.
8. Mallas EG, Mackintosh R, Asquith P. Histocompatibility antigens in inflammatory bowel disease: their clinical significance and their association with arthropathy with special reference to HLA B27. Gut 1976; 17: 906-10.
9. Scarpa R, Del Puente A, D'Arienzo A, et al. The arthritis of ulcerative colitis: clinical and genetic aspects. J Rheumatol 1992; 19: 375-7.
10. Purrman J, Zeidler H, Bertrams J, et al. HLA antigens in ankylosing spondylitis associated with Crohn's disease. Increased frequency of the HLA phenotype B27, B44. J Rheumatol 1988; 15: 1658-61.
11. Robinson WP, van der Linden SM, Khan MA, et al. HLA-Bw60 increases susceptibility by ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum 1989; 32: 1135-41.
12. Mielants H, Veys EM, Cuvelier C, De Vos M. Hecolonoscopic Undings in seronegative spondyloarthropathies. Br J Rheumatol 1988; 27: 95-105.
13. De Vos M, Cuvelier C, Mielants H, et al. Heocolonscopy in seronegative spondyloarthropathy. Gastroenterology 1989; 96: 339-44.
14. Dougados M, Allemanni M, Tulliez M, et al. Iléocolonoscopie systhématique au cours des spondyloarthropathies séronégatives. Rev Rhum 1987; 54: 279-83.
15. Simenon G, Van Gossum A, Adler M, et al. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990; 17: 491-4.
16. Altomente L., Zoli A, Veneziania A, et al. Clinical silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 1994; 13: 565-70.
17. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum 1994; 37: 23-31.
18. Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol 1995; 22: 680-3.
19. Mielants H, Veys EM, Joos R, et al. Late onset pauciarticular juvenile chronic arthritis: relation to gut inflammation. J Rheumatol 1987; 14: 459-65.
20. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987; 28: 394-401.
21. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696-703.
22. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63: 109-12.
23. Cuvelier C, Mielants H, De Vos M, et al. Major histocompatibility class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondyloarthropathies. Gut 1990; 31: 545-9.
24. Cuvelier CA, Quatacker J, Mielants H, et al. M-cells are damaged and increased in number in inflamed human ileal mucosa. Histopathology 1994; 24: 417-26.
25. Salmi M, Andrew DP, Butcher EC, et al. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995; 181: 137-49.
26. Adams DH, Shaw S. Leucocyte - endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831-6.
27. Picker LJ. Control of lymphocyte homing. Curr Opin Immunol 1994; 6: 394-406.
28. Elewaut D, De Vos M, De Keyser F, et al. Distinctive cell activation markers in colon from patients with Crohn's disease and ulcerative colitis. Gastroenterology 1997; 112: A718.
29. Elewaut D, De Keyser F, Lazarovits A, et al. Inflamed synovial tissue from patients with spondyloarthropathy is enriched with activated T-cells carrying β7 integrins. Arthritis Rheum 1996; 39: S162.
30. Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints: distinct endothelial ligands in synovium mediate leukocyte subtype specific adhesion. J Clin Invest 1997; 99: 2165-72.
31. Kaufman HL, Fischer AH, Carroll M, Becker JM. Colonic ulceration associated with nonsteroidal antiinflammatory drugs. Dis Colon Rectum 1996; 39: 705-10.
32. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). Arthritis Rheum 1996; 39: 2021-7.
33. Creemers MCW, Van Riel PLCM, Franssen MJAM, et al. Second-line treatment in seronegative spondyloarthropathies. Sem Arthritis Rheum 1994; 24: 71-81.
34. Taggart AJ, Gardiner P, McEvoy FM, et al. Which is the active moiety of sulphasalazine in ankylosing spondylitis? Arthritis Rheum 1996; 39: 1400-5.
35. Clegg Do, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996; 39: 2004-12.
36. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy. Arthritis Rheum 1995; 38: 618-27.
37. Compston JE. Review article: osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmocal Ther 1995; 9: 237-50.
38. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-22.
39. Roux C, Abithol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 156-60.
40. Vogelsang H, Klamert M, Resch H, Ferenci P. Dietary vitamin D intake in patients with Crohn's disease. Wien Klin Wochenschr 1995; 19: 578-81.
41. Bjarnason I, MacPherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-33.
42. Motley RJ, Clements D, Evans WD, et al. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993; 23: 95-104.
43. Clements D, Motley RJ, Evans WD, et al. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992; 27: 1055-60.
44. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-15.
45. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis 1992; 37: 1396-403.
46. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031-9.
47. Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
48. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease. A longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997; 32: 226-32.
49. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by longterm oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609-14.
50. Croucher PI, Vedi S, Motley RJ, et al. Reduced bone information bone formation in patients with oesteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993; 3: 236-41.
51. Hessov I, Mosekilde L, Meisen F, et al. Osteopenia with normal vitamin D metabolites after small bowel resection for Crohn's disease. Scand J Gastroenterol 1984; 19: 691-6.
52. Lukert BP, Raisz LG. Glucocorticoid induced osteoporosis pathogenesis and management. Ann Intern Med 1990; 112: 352-64.
53. Bernstein CN, Seeger LL, Sayre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-6.
54. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-19.
55. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83: 1252-8.
56. Lin CL, Moniz C, Chambers TJ, Chow JWM. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111: 1263-71.
57. MacDonald BR, Gowen M. Cytokines and bone (review). Br J Rheumatol 1992; 31: 149-55.
58. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543-6.
59. Francis RM, Peacock M, Aaron JE. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption and low bone formation. Bone 1986; 7: 261-8.
60. Silvennoinen JA, Lehtola JK, Niemelä SE. Smoking is a risk factor lor osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996; 51: 364-71.
61. Bernstein CN, Seeger LL, Anton PA, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 777-86.
62. Adachi JD, Bensen WG, Brown J, et al. Intermittent eridronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl J Med 1997; 337: 382-7.
63. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112: 1710-13.
64. MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD. Biochemical markers of bone turnover in seronegative spondyloarthropathy: relationship to disease activity. Br J Rheumatol 1997; 36: 50-3.
65. Marhoffer W, Stracke H, Masoud I, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995; 54: 556-9.